Research published in Nature Biomedical Engineering demonstrates NuProbe’s technology can enable detecting single nucleotide variants (SNVs) in DNA with a variant allele frequency (VAF) of ≤0.02% using a sequencing depth of only 250x.
Read More
Rapid Development
Sensitive Mutation, Indel, and CNV Detection
Low Input DNA
Gene Selection and Coverage options
VarMap™: NGS
Features
Affordable
Only 1 million reads for liquid biopsy
Ultrasensitive
Limit of detection down to 0.1% VAF
Quantitative
>95% VAF quantitation accuracy
Sample Flexibility
Compatible with several sample types
Sample Data
VarMap NGS Panels preferentially amplify variant molecules, resulting in a reduction of required sequencing reads by 60-fold compared to deep sequencing approaches.
Products
VarMap™ Pan-Cancer NGS Panel
Detects over 6300 COSMIC mutations in over 60 genes
CNV+: NGS
Features
Ultrasensitive
Limit of detection down to 0.1% VAF
Quantitative
>95% VAF quantitation accuracy
Quick Turnaround Time
6-hour DNA-to-Library workflow
Sample Flexibility
Compatible with several sample types
Sample Data
CNV+ panels use QASeq technology, which is more sensitive than ddPCR. The panels detect deletions and mutations, that can not be done with IHC. QASeq technology allows analyzing thousands of loci, while ddPCR analyzes 1 locus.
Products
CNV+ Breast Cancer NGS Panel
Detects 84 mutation hotspots in 14 genes and detect ERBB2 Copy Number Variations (CNVs) in a single reaction
VarTrace®: qPCR, Sanger
Features
Ultrasensitive
Limit of detection down to 0.1% VAF
Comprehensive
Detects up to 500 COSMIC mutations
Quantitative
Accurate quantitation
Sample Flexibility
Compatible with several sample types
Sample Data
NuProbe’s BDA technology enriches the variant allele frequency (VAF) of mutations by over 200-fold, improving Sanger’s limit of detection of 20% VAF to 0.1% VAF.
Products
VarTrace® AML Panel
Detects 254 AML hotspot mutations in FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 genes
VarTrace® EGFR Assay
Detects 400 mutations in exons 18, 19, 20, and 21 in FFPE and plasma samples
VarTrace® BRAF Assay
Detects mutations in codons 596–601 in FFPE and plasma samples
Customized qPCR/Sanger Assays and Services
Features
Customizable
Automatically design custom BDA assays
Rapid Turnaround
2-3 days
Ultrasensitive
Limit of detection down to 0.1% VAF
Sample Data
NGSure’s proprietary algorithm designs custom BDA assays with a limit of detection of 0.1% VAF, significantly expanding the range of mutations detected by NGS.
News & Press Releases
The VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes. The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF.
The lead investors for this financing round are BioTrack Capital and Yonghua Capital. The proceeds will be used to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.
NuProbe launches the Augury™ platform for automated design of customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury™ will procedurally generate NGS panels for cell-free DNA (cfDNA) analysis, covering the entire coding regions of between 1 and 30 genes of interest.
NuProbe and Weigao Group will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to later apply for in vitro diagnostic (IVD) registration with NMPA, China’s equivalent of FDA.
The first, Non-Extensible Oligonucleotides (NEO), will allow NuProbe to provide much more rapid development of customized NGS panels, with turnaround time of less than 4 weeks. The second, Linear DNA Assembly (LDA) technology, improves the effective throughput of nanopore sequencing by up to 10-fold for short DNA, such as DNA extracted from FFPE tumor tissues and cell-free DNA from peripheral blood. Concurrently, NuProbe announces the launch of its new VarMap™ Nanopore product line.
Upcoming Events
May 17-21, 2021
AACR 2021 Virtual Meeting
June 09–12, 2021
EACR 2021 Virtual Congress
June 12–15, 2021
ESHG Conference 2021
